Literature DB >> 23448294

Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis.

Hans Linde Nielsen1, Jørgen Engberg, Tove Ejlertsen, Henrik Nielsen.   

Abstract

Calprotectin (CP) is a calcium-binding cytosolic neutrophil protein and the concentration in feces reflects the migration of neutrophils into the gut lumen. Testing for fecal CP (f-CP) in patients with negative cultures for enteric pathogens is widely accepted as a useful screening tool for identifying patients who are most likely to benefit from endoscopy for suspected inflammatory bowel disease (IBD) with the assumption that a negative f-CP is compatible with a functional disorder. Campylobacter concisus has recently been reported to have a high incidence in the Danish population almost equal to Campylobacter jejuni and Campylobacter coli and has been reported to cause prolonged watery diarrhea. However, isolation of C. concisus from feces requires the filter method in a hydrogen-enriched microaerobic atmosphere, which is not commonly used in the laboratory, and the diagnosis may consequently be missed. The aim of this study was to evaluate the f-CP levels, as a marker for the intestinal inflammation in C. jejuni/coli- and C. concisus-infected patients. The authors found a high concentration of f-CP (median 631: IQR 221-1274) among 140 patients with C. jejuni/coli infection, whereas the f-CP level among 99 C. concisus-infected patients was significantly lower (median 53: IQR 20-169). The data correlate to the severe inflammatory gastroenteritis seen in patients infected with C. jejuni/coli, whereas C. concisus-infected patients have a much lower intestinal inflammation which could be compared with viral gastroenteritis. Nevertheless, clinicians should be aware of C. concisus infection, especially in patients with prolonged mild diarrhea, in the differential diagnosis to IBD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448294     DOI: 10.3109/00365521.2013.775329

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 2.  Global Epidemiology of Campylobacter Infection.

Authors:  Nadeem O Kaakoush; Natalia Castaño-Rodríguez; Hazel M Mitchell; Si Ming Man
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  A randomized controlled trial investigating the effect of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols on the intestinal microbiome and inflammation in patients with ulcerative colitis: study protocol for a randomized controlled trial.

Authors:  Alireza Milajerdi; Omid Sadeghi; Seyed Davar Siadat; Seyed Ali Keshavarz; Alireza Sima; Homayoon Vahedi; Peyman Adibi; Ahmad Esmaillzadeh
Journal:  Trials       Date:  2020-02-18       Impact factor: 2.279

Review 4.  Fecal calprotectin in inflammatory bowel disease.

Authors:  Natalie E Walsham; Roy A Sherwood
Journal:  Clin Exp Gastroenterol       Date:  2016-01-28

5.  Campylobacter concisus Impairs Sodium Absorption in Colonic Epithelium via ENaC Dysfunction and Claudin-8 Disruption.

Authors:  Praveen Kumar Nattramilarasu; Roland Bücker; Fábia Daniela Lobo de Sá; Anja Fromm; Oliver Nagel; In-Fah Maria Lee; Eduard Butkevych; Soraya Mousavi; Claudia Genger; Sigri Kløve; Markus M Heimesaat; Stefan Bereswill; Michal R Schweiger; Hans Linde Nielsen; Hanno Troeger; Jörg-Dieter Schulzke
Journal:  Int J Mol Sci       Date:  2020-01-07       Impact factor: 5.923

Review 6.  Calprotectin: from biomarker to biological function.

Authors:  Almina Jukic; Latifa Bakiri; Erwin F Wagner; Herbert Tilg; Timon E Adolph
Journal:  Gut       Date:  2021-06-18       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.